Key Drivers
- Strong Liquidity
- Higher Leverage
- Weak FCF
AIAI Summary
TMDX has shifted from a high-growth medtech story to a prove-it name, where solid revenue growth and attractive gross margins are being overshadowed by negative free cash flow, rising debt, and a market that now needs evidence of sustainable cash conversion and disciplined execution before re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Higher Leverage
- •Weak FCF
TMDX remains fundamentally strong with excellent liquidity and solid operating margins, but higher leverage and a recent free-cash-flow decline make the balance sheet and cash generation the main watchpoints.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support failure
- •Oversold bounce
Over the last month, TMDX plunged from $115.87 to $63.20 in a clear lower-high/lower-low breakdown, leaving it oversold but still firmly bearish with near-term resistance at $67.84 and $72.90-$72.92 and a more meaningful recovery only above $90-$100.
Sharp selloff from $115.87 to the low-$60s over the last month, accelerating after $100 support broke
Sentiment & News
Key News Insights:
- •Clinical Expansion
- •Margin Pressure
- •Valuation Debate
TransMedics is expanding its clinical, product, and European logistics footprint, but a Q1 earnings miss, margin pressure, and a rich valuation keep execution risk front and center.
The news supports long-term growth prospects, but near-term upside may stay capped until margins and execution improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings